The estimated Net Worth of Suzanne Blaug is at least $804 Tausend dollars as of 7 June 2023. Ms. Blaug owns over 8,520 units of FibroGen Inc stock worth over $11,838 and over the last 5 years she sold FGEN stock worth over $146,544. In addition, she makes $645,490 as Independent Director at FibroGen Inc.
Sign up
Ms. Blaug FGEN stock SEC Form 4 insiders trading
Suzanne has made over 1 trades of the FibroGen Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently she sold 8,520 units of FGEN stock worth $146,544 on 7 June 2023.
The largest trade she's ever made was selling 8,520 units of FibroGen Inc stock on 7 June 2023 worth over $146,544. On average, Suzanne trades about 1,420 units every 0 days since 2019. As of 7 June 2023 she still owns at least 29,594 units of FibroGen Inc stock.
You can see the complete history of Ms. Blaug stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Suzanne Blaug biography
Suzanne Blaug serves as Independent Director of the Company. She has successfully brought new drugs to market at the global, regional, and local country levels in multiple therapeutic areas including Oncology, Cardiovascular, Immunology, Nephrology, Infectious Diseases, Neurology, and Psychiatry. Ms. Blaug most recently served as Senior Vice President, Global Marketing and Commercial Development at Amgen Inc. from 2012 to 2018. From 2004 until 2012, she was at Johnson & Johnson, where she held several positions including Head of Janssen Alzheimer Immunotherapy, Vice President Strategic Marketing and New Business Development at Janssen Europe, and Area Managing Director – UK, Italy, and Greece. Ms. Blaug started her career at Bristol-Myers Squibb in 1983, where she held numerous marketing, strategic, and general management positions in the U.S., Europe, Australia, and New Zealand. Ms. Blaug is currently a senior advisor at McKinsey & Company, and she serves on the Healthcare at Kellogg Advisory Council at Northwestern University, as well as the Center for the Business of Healthcare Corporate Advisory Board at the University of North Carolina. Ms. Blaug received her Bachelor of Science degree from the University of North Carolina at Chapel Hill, and her Master of Business Administration degree from the Kellogg School of Management at Northwestern University.
What is the salary of Suzanne Blaug?
As the Independent Director of FibroGen Inc, the total compensation of Suzanne Blaug at FibroGen Inc is $645,490. There are 8 executives at FibroGen Inc getting paid more, with Kin-Hung Yu having the highest compensation of $5,856,450.
How old is Suzanne Blaug?
Suzanne Blaug is 62, she's been the Independent Director of FibroGen Inc since 2019. There are 8 older and 13 younger executives at FibroGen Inc. The oldest executive at FibroGen Inc is Thomas Kearns, 83, who is the Lead Independent Director.
What's Suzanne Blaug's mailing address?
Suzanne's mailing address filed with the SEC is C/O FIBROGEN, INC., 409 ILLINOIS ST., SAN FRANCISCO, CA, 94158.
Insiders trading at FibroGen Inc
Over the last 10 years, insiders at FibroGen Inc have traded over $188,593,537 worth of FibroGen Inc stock and bought 106,523 units worth $1,309,423 . The most active insiders traders include Rory B Riggs, Thomas B Neff und Jeffrey William Henderson. On average, FibroGen Inc executives and independent directors trade stock every 8 days with the average trade being worth of $6,963. The most recent stock trade was executed by Deyaa Adib on 12 June 2024, trading 22,123 units of FGEN stock currently worth $25,884.
What does FibroGen Inc do?
fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.
What does FibroGen Inc's logo look like?
Complete history of Ms. Blaug stock trades at FibroGen Inc
FibroGen Inc executives and stock owners
FibroGen Inc executives and other stock owners filed with the SEC include:
-
Kin-Hung Yu,
Chief Medical Officer -
James Schoeneck,
Chairman of the Board -
Elias Kouchakji,
Senior Vice President, Clinical Development, Drug Safety and Pharmacovigilance -
Christine Chung,
Senior Vice President, China Operations -
Pat Cotroneo,
Chief Financial Officer -
Enrique A. Conterno,
CEO & Director -
Dr. Elias Kouchakji,
Sr. VP of Clinical Devel., Drug Safety & Pharmacovigilance -
Pat Cotroneo,
Exec. Advisor to CEO -
Suzanne Blaug,
Independent Director -
Thane Wettig,
Chief Commercial Officer -
Dr. Mark Eisner M.D., M.P.H.,
Chief Medical Officer -
Thomas Kearns,
Lead Independent Director -
Jeffrey Edwards,
Independent Director -
Rory Riggs,
Independent Director -
Gerald Lema,
Independent Director -
Jeffrey Henderson,
Independent Director -
Maykin Ho,
Independent Director -
Kalevi Kurkijarvi,
Independent Director -
Toshinari Tamura,
Independent Director -
James A. Schoeneck,
Chairman -
Benjamin Cravatt,
Director -
Aoife Brennan,
Director -
Thane Wettig,
Chief Commercial Officer -
Percy Carter,
Chief Scientific Officer -
Enrique Conterno,
Chief Executive Officer, Director -
Dr. John J. Hunter Ph.D.,
Chief Scientific Officer -
Dr. Michael J. Martinelli,
Sr. VP of Technical Devel. -
Juan Graham,
Chief Financial Officer -
Dr. Barry A. Berkowitz Ph.D.,
Founder -
Jorma Routti,
Director -
K Peony Yu,
Chief Medical Officer -
Thomas B Neff,
Chief Executive Officer -
Mark Eisner,
EVP, Chief Medical Officer -
Julian N Stern,
Director -
Frank H Md Valone,
Chief Medical Officer -
Miguel Madero,
Director -
Pharma Inc. Astellas,
-
Juan Graham,
CHIEF FINANCIAL OFFICER -
Deyaa Adib,
Chief Medical Officer